Akari Therapeutics (AKTX) to Release Earnings on Tuesday

Akari Therapeutics (NASDAQ:AKTX) will likely be announcing its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect Akari Therapeutics to announce earnings of ($1.04) per share for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 4:00 PM ET.

Akari Therapeutics Stock Up 7.6%

NASDAQ AKTX opened at $7.53 on Tuesday. The stock has a 50-day moving average of $11.23 and a two-hundred day moving average of $9.12. Akari Therapeutics has a 1-year low of $3.02 and a 1-year high of $49.60.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on AKTX shares. Wall Street Zen lowered shares of Akari Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 25th. Maxim Group upgraded shares of Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a report on Monday, July 20th. Finally, Weiss Ratings upgraded shares of Akari Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Akari Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $32.33.

Institutional Investors Weigh In On Akari Therapeutics

A hedge fund recently bought a new stake in Akari Therapeutics stock. Armistice Capital LLC bought a new stake in Akari Therapeutics PLC (NASDAQ:AKTX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned about 5.95% of Akari Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.